PDMR Dealing / Grant of Share Options

Oxford BioDynamics grants CEO Richard Compton options equal to 7.5% of share capital.

What the company is saying

Oxford BioDynamics Plc has granted Chief Executive Officer Richard Compton 1,008,068,322 share options, representing 7.5% of the current issued share capital, under its 2016 Employee Share Option Plan. The grant is structured in three equal tranches of 336,022,774 options each, with exercise prices of 0.115 pence, 0.1725 pence (a 50% premium), and 0.23 pence (a 100% premium), vesting in monthly tranches over three years. The company highlights Compton’s resulting direct shareholding of 300,000,000 ordinary shares, or 2.23% of the issued capital. The announcement also reiterates the company’s operational strengths, including the EpiSwitch PSE test (which increases PSA test accuracy from 55% to 94%), the EpiSwitch CiRT test (85% predictive accuracy), and the EpiSwitch Orion platform, supported by over 1.5 billion data points and 15 million genomic connections validated across 18,000+ patient samples. The company references more than 40 collaborations with major pharmaceutical and academic partners, and recent funding awards from US and EU research programs. The tone is factual and focused on both the mechanics of the option grant and the scale of the company’s technology and partnerships.

What the data suggests

The grant of 1,008,068,322 options to the CEO is substantial, equating to 7.5% of the company’s current issued share capital. Each tranche of 336,022,774 options has a different exercise price, with the highest set at a 100% premium to the most recent market price, and vesting is staggered over 36 months in monthly increments. The options become exercisable from 18 September 2027 and remain so for ten years from grant. Richard Compton’s direct shareholding after this grant stands at 300,000,000 shares, or 2.23% of issued capital. The company’s operational disclosures are specific: the EpiSwitch PSE test improves PSA test accuracy from 55% to 94%, and the CiRT test offers 85% predictive accuracy. The EpiSwitch Orion platform is supported by a knowledgebase of over 1.5 billion data points and 15 million genomic connections, validated across more than 18,000 patient samples in over 40 diseases. The company has completed over 40 collaborations with major industry and academic partners. No financial performance data, such as revenue or profit, is included in this announcement.

Analysis

The announcement is a factual disclosure of a large CEO share option grant, with detailed breakdowns of tranches, exercise prices, vesting schedules, and resulting shareholdings. The operational summary of the company's products, platform, and collaborations is descriptive but does not make exaggerated claims or overstate realised progress. Most statements are realised facts (option grant, product metrics, collaborations), with only a minor portion referencing future potential (e.g., new tests in development). There is no promotional or inflated language, and no large capital outlay or long-dated, uncertain returns are discussed. The absence of financial performance data is not a deficiency here, as this is a personnel/option grant disclosure. The tone is positive but proportionate to the content.

Risk flags

• ●The grant of options equal to 7.5% of issued share capital to a single executive concentrates a significant portion of potential future equity in the hands of the CEO, raising key-person dependency and potential dilution risk for existing shareholders if exercised.
• ●The absence of financial performance data in this announcement means investors cannot assess the company’s current revenue, cash position, or profitability, limiting visibility into the company’s ability to support long-term incentive plans.
• ●The ambitious scale of the company’s technology platform and product claims is not matched by disclosed commercial adoption or revenue figures, so the operational achievements described may not yet translate into financial returns.

Bottom line

This is a routine but large-scale option grant, giving CEO Richard Compton the right to acquire shares equal to 7.5% of Oxford BioDynamics’ current capital over the next decade, with vesting spread across three years and exercise prices set at up to double the current market level. The company uses the announcement to reinforce the scale and technical credibility of its platform, citing strong product metrics and a large knowledgebase, but does not provide any financial performance data or evidence of commercial traction. For investors, the main takeaway is that management incentives are now heavily aligned with future share price appreciation, but the lack of financial disclosure leaves open questions about the company’s near-term commercial momentum. The most actionable fact is the scale and structure of the CEO’s new option package; further updates on revenue or commercial partnerships would be needed to clarify the company’s growth trajectory.

Announcement summary

(AIM:OBD, LSE:OBD) Oxford BioDynamics Plc announced the grant of a total of 1,008,068,322 share options over its ordinary shares of 0.1 pence each to Chief Executive Officer Richard Compton on 18 September 2026. The options were granted under the Company’s 2016 Employee Share Option Plan and are divided into three tranches: 336,022,774 options at an exercise price of 0.115 pence per share, vesting in 12 equal tranches over the first 12 months; 336,022,774 options at an exercise price of 0.1725 pence per share, representing a 50% premium over the closing mid-market price on 17 September 2026, vesting in 12 equal tranches between months 13 and 24; and 336,022,774 options at an exercise price of 0.23 pence per share, representing a 100% premium, vesting in 12 equal tranches between months 25 and 36. The options will be exercisable at any time from 18 September 2027 upon vesting and will remain exercisable up to and including the tenth anniversary of the date of grant. Following this grant, Richard Compton’s shareholding in the Company is 300,000,000 ordinary shares, representing 2.23% of the current issued share capital, and his options over ordinary shares represent 7.50% of the current issued share capital. The ISIN for the ordinary shares is GB00BD5H8572. The Company’s proprietary products include the EpiSwitch PSE (Prostate Cancer Detection Test), which increases the predictive accuracy of a PSA test from 55% to 94%, and the EpiSwitch CiRT (Checkpoint Inhibitor Response Test), which has an 85% predictive accuracy. The EpiSwitch Orion platform is a cloud-based 3D genomics platform supported by a knowledgebase featuring over 1.5 billion data points and 15 million high-confidence genomic connections validated across 18,000+ patient samples in more than 40 diseases. The Company has participated in more than 40 collaborations with pharmaceutical and academic partners, including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital, and Mitsubishi Tanabe Pharma America. OBD has been awarded funding through the US Foundation for the National Institutes of Health's Partnership for Accelerating Cancer Therapies programme and the EU-funded HIPPOCRATES consortium in psoriatic arthritis. The Company’s headquarters and UK laboratories are in Oxford, United Kingdom, with US operations and a clinical laboratory in Maryland, USA, and a reference laboratory in Penang, Malaysia.

Disagree with this article?